Influence of Low-Density Lipoprotein Cholesterol Levels on NSAID-Associated Cardiovascular Risks After Myocardial Infarction: A Population-Based Cohort Study
DOI: https://doi.org/10.2147/clep.s447451
2024-04-23
Clinical Epidemiology
Abstract:Mohab Basem, 1 Kasper Bonnesen, 1 Lars Pedersen, 1 Henrik Toft Sørensen, 1 Morten Schmidt 1, 2 1 Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark; 2 Department of Cardiology, Gødstrup Regional Hospital, Herning, Denmark Correspondence: Mohab Basem, Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Olof Palmes Allé 43– 45, Aarhus N, 8200, Denmark, Tel +45 87167212, Email Aim: To examine whether low-density lipoprotein cholesterol (LDL-C) levels influence the cardiovascular risk associated with non-aspirin non-steroidal anti-inflammatory drug (NSAID) use after myocardial infarction (MI). Methods: Using Danish health registries, we conducted a population-based cohort study of all adult patients with first-time MI during 2010– 2020 with an LDL-C value before discharge. Based on the latest LDL-C value, we categorized patients into a low and a high LDL-C group (< 3.0 vs ≥ 3.0 mmol/L). We used time varying Cox regression to compute hazard ratios (HRs) with 95% confidence intervals of the association between NSAID use and a major adverse cardiovascular event (MACE: recurrent MI, ischemic stroke, and all-cause death). Results: We followed 50,573 patients for a median of 3.1 years. While exposed, 521 patients experienced a MACE: 312 in the low LDL-C group and 209 in the high LDL-C group. The HRs for MACE comparing NSAID use with non-use were 1.21 (1.11– 1.32) overall, 1.19 (1.06– 1.33) in the low LDL-C group, and 1.23 (1.07– 1.41) in the high LDL-group. The HRs for recurrent MI and ischemic stroke were comparable between the LDL-C subgroups. The HRs for all-cause death were 1.22 (1.07– 1.39) in the low LDL-C group and 1.54 (1.30– 1.83) in the high LDL-C group. Changing the cut-off value for LDL-C to 1.8 and 1.4 mmol/L showed consistent results. Conclusion: In patients with MI, LDL-C levels did not influence the increased risk of MACE associated with NSAID use, but might influence the association between NSAID use and all-cause death. Keywords: cardiovascular disease, non-steroidal anti-inflammatory drugs, cholesterol, low-density lipoprotein cholesterol, myocardial infarction, effect modification Graphical Non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat pain, fever, and inflammation. 1 In Denmark, about 15% of the population fill at least one NSAID prescription annually. 2 In patients with acute myocardial infarction (MI), NSAID use has been associated with increased risk of recurrent MI, 3–6 ischemic stroke, 7 atrial fibrillation, 3,8 and death. 3,4,6 Consequently, it is recommended that NSAIDs should be used with caution in patients with MI, as they are already at high risk of cardiovascular disease. 9–11 Nevertheless, approximately 9% of Danish patients with first-time MI fill an NSAID prescription within a year. 10 Frequent NSAID use in patients with MI might be explained by the improved survival of MI patients, and hence as they get older stand a higher chance of acquiring conditions associated with chronic pain. 12,13 Therefore, as NSAID use already confers an increased cardiovascular risk, it is crucial to guide NSAID use in patients with, or at high risk of, cardiovascular disease. 3,4,11 A well-established risk factor for cardiovascular disease is high levels of low-density lipoprotein cholesterol (LDL-C). 9,14,15 The European Society of Cardiology warns against the use of NSAIDs in high-risk individuals including those with dyslipidemia. 16 However, no studies have investigated whether patients' LDL-C levels influence the association between NSAID use and cardiovascular events. Therefore, we investigated the association between NSAID use and cardiovascular events within strata of LDL-C levels among patients with first-time MI. The Danish healthcare system provides universal tax-supported healthcare to all Danish citizens and legal residents, guaranteeing free access to general practitioners and hospitals, as well as partial reimbursement for the costs of prescription drugs, including NSAIDs. 17 The unique Civil Personal Register number, assigned to all Danish citizens at birth and to residents upon immigration, allows individual-level linkage among Danish registries and ensures almost complete follow-up with accurate censoring at death or emigration. 18 We used the Danish National Patient Registry (DNPR) to identify all adult (≥18 years of age) patients with a first-time primary and secondary inpatient MI diagnosis from 1 January 2010 until 31 December 2020 -Abstract Truncated-
public, environmental & occupational health